FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news